 | • レポートコード：MRC2312MG07559 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の臨床全エクソームシーケンス（WES）市場規模と予測を収録しています。・世界の臨床全エクソームシーケンス（WES）市場：売上、2018年-2023年、2024年-2029年 ・世界の臨床全エクソームシーケンス（WES）市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の臨床全エクソームシーケンス（WES）市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アレイベースエクソーム濃縮」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 臨床全エクソームシーケンス（WES）のグローバル主要企業は、CentoXome、 Mayo Clinic Laboratories、 Baylor Genetics、 Blueprint Genetics、 GeneDx、 CD Genomics、 Illumina、 Thermo Fisher、 Labassure、 Yale Medicine、 Genosalut、 Caris Life Sciences、 InterGenetics、 Genomics and Pathology Services (GPS)、 3billion、 Broad Genomic、 Roche、 Novogene、 BGI Genomics、 Shanghai Jingzhou Genomics、 Shihe Gene Biotechnology、 JUNO Genomicsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、臨床全エクソームシーケンス（WES）のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の臨床全エクソームシーケンス（WES）市場：タイプ別、2018年-2023年、2024年-2029年 世界の臨床全エクソームシーケンス（WES）市場：タイプ別市場シェア、2022年 ・アレイベースエクソーム濃縮、ビオチン化プローブ使用溶液中エクソーム濃縮 世界の臨床全エクソームシーケンス（WES）市場：用途別、2018年-2023年、2024年-2029年 世界の臨床全エクソームシーケンス（WES）市場：用途別市場シェア、2022年 ・希少遺伝病、遺伝子検査不合格、その他 世界の臨床全エクソームシーケンス（WES）市場：地域・国別、2018年-2023年、2024年-2029年 世界の臨床全エクソームシーケンス（WES）市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における臨床全エクソームシーケンス（WES）のグローバル売上、2018年-2023年 ・主要企業における臨床全エクソームシーケンス（WES）のグローバル売上シェア、2022年 ・主要企業における臨床全エクソームシーケンス（WES）のグローバル販売量、2018年-2023年 ・主要企業における臨床全エクソームシーケンス（WES）のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 CentoXome、 Mayo Clinic Laboratories、 Baylor Genetics、 Blueprint Genetics、 GeneDx、 CD Genomics、 Illumina、 Thermo Fisher、 Labassure、 Yale Medicine、 Genosalut、 Caris Life Sciences、 InterGenetics、 Genomics and Pathology Services (GPS)、 3billion、 Broad Genomic、 Roche、 Novogene、 BGI Genomics、 Shanghai Jingzhou Genomics、 Shihe Gene Biotechnology、 JUNO Genomics ************************************************************* ・調査・分析レポートの概要 臨床全エクソームシーケンス（WES）市場の定義 市場セグメント 世界の臨床全エクソームシーケンス（WES）市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の臨床全エクソームシーケンス（WES）市場規模 世界の臨床全エクソームシーケンス（WES）市場規模：2022年 VS 2029年 世界の臨床全エクソームシーケンス（WES）市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの臨床全エクソームシーケンス（WES）の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の臨床全エクソームシーケンス（WES）製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：アレイベースエクソーム濃縮、ビオチン化プローブ使用溶液中エクソーム濃縮 臨床全エクソームシーケンス（WES）のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：希少遺伝病、遺伝子検査不合格、その他 臨床全エクソームシーケンス（WES）の用途別グローバル売上・予測 ・地域別市場分析 地域別臨床全エクソームシーケンス（WES）市場規模 2022年と2029年 地域別臨床全エクソームシーケンス（WES）売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） CentoXome、 Mayo Clinic Laboratories、 Baylor Genetics、 Blueprint Genetics、 GeneDx、 CD Genomics、 Illumina、 Thermo Fisher、 Labassure、 Yale Medicine、 Genosalut、 Caris Life Sciences、 InterGenetics、 Genomics and Pathology Services (GPS)、 3billion、 Broad Genomic、 Roche、 Novogene、 BGI Genomics、 Shanghai Jingzhou Genomics、 Shihe Gene Biotechnology、 JUNO Genomics ... |
This research report provides a comprehensive analysis of the Clinical Whole Exome Sequencing (WES) market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Clinical Whole Exome Sequencing (WES) market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Clinical Whole Exome Sequencing (WES), challenges faced by the industry, and potential opportunities for market players.
The global Clinical Whole Exome Sequencing (WES) market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Clinical Whole Exome Sequencing (WES) market presents opportunities for various stakeholders, including Rare Genetic Disease, Genetic Testing Unsuccessful. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Clinical Whole Exome Sequencing (WES) market. Additionally, the growing consumer demand present avenues for market expansion.
The global Clinical Whole Exome Sequencing (WES) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Clinical Whole Exome Sequencing (WES) market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Clinical Whole Exome Sequencing (WES) market.
Market Overview: The report provides a comprehensive overview of the Clinical Whole Exome Sequencing (WES) market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Array-Based Exome Enrichment, Enrichment of the Exome in Solution using Biotinylated Probes), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Clinical Whole Exome Sequencing (WES) market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Clinical Whole Exome Sequencing (WES) market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Clinical Whole Exome Sequencing (WES) market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Clinical Whole Exome Sequencing (WES) market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Clinical Whole Exome Sequencing (WES) market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Clinical Whole Exome Sequencing (WES) market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Clinical Whole Exome Sequencing (WES), including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Clinical Whole Exome Sequencing (WES) market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Clinical Whole Exome Sequencing (WES) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Array-Based Exome Enrichment
Enrichment of the Exome in Solution using Biotinylated Probes
Market segment by Application
Rare Genetic Disease
Genetic Testing Unsuccessful
Others
Global Clinical Whole Exome Sequencing (WES) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
CentoXome
Mayo Clinic Laboratories
Baylor Genetics
Blueprint Genetics
GeneDx
CD Genomics
Illumina
Thermo Fisher
Labassure
Yale Medicine
Genosalut
Caris Life Sciences
InterGenetics
Genomics and Pathology Services (GPS)
3billion
Broad Genomic
Roche
Novogene
BGI Genomics
Shanghai Jingzhou Genomics
Shihe Gene Biotechnology
JUNO Genomics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Clinical Whole Exome Sequencing (WES), market overview.
Chapter 2: Global Clinical Whole Exome Sequencing (WES) market size in revenue.
Chapter 3: Detailed analysis of Clinical Whole Exome Sequencing (WES) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Clinical Whole Exome Sequencing (WES) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Clinical Whole Exome Sequencing (WES) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Clinical Whole Exome Sequencing (WES) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Clinical Whole Exome Sequencing (WES) Overall Market Size
2.1 Global Clinical Whole Exome Sequencing (WES) Market Size: 2022 VS 2029
2.2 Global Clinical Whole Exome Sequencing (WES) Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Clinical Whole Exome Sequencing (WES) Players in Global Market
3.2 Top Global Clinical Whole Exome Sequencing (WES) Companies Ranked by Revenue
3.3 Global Clinical Whole Exome Sequencing (WES) Revenue by Companies
3.4 Top 3 and Top 5 Clinical Whole Exome Sequencing (WES) Companies in Global Market, by Revenue in 2022
3.5 Global Companies Clinical Whole Exome Sequencing (WES) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Clinical Whole Exome Sequencing (WES) Players in Global Market
3.6.1 List of Global Tier 1 Clinical Whole Exome Sequencing (WES) Companies
3.6.2 List of Global Tier 2 and Tier 3 Clinical Whole Exome Sequencing (WES) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Clinical Whole Exome Sequencing (WES) Market Size Markets, 2022 & 2029
4.1.2 Array-Based Exome Enrichment
4.1.3 Enrichment of the Exome in Solution using Biotinylated Probes
4.2 By Type – Global Clinical Whole Exome Sequencing (WES) Revenue & Forecasts
4.2.1 By Type – Global Clinical Whole Exome Sequencing (WES) Revenue, 2018-2023
4.2.2 By Type – Global Clinical Whole Exome Sequencing (WES) Revenue, 2024-2029
4.2.3 By Type – Global Clinical Whole Exome Sequencing (WES) Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Clinical Whole Exome Sequencing (WES) Market Size, 2022 & 2029
5.1.2 Rare Genetic Disease
5.1.3 Genetic Testing Unsuccessful
5.1.4 Others
5.2 By Application – Global Clinical Whole Exome Sequencing (WES) Revenue & Forecasts
5.2.1 By Application – Global Clinical Whole Exome Sequencing (WES) Revenue, 2018-2023
5.2.2 By Application – Global Clinical Whole Exome Sequencing (WES) Revenue, 2024-2029
5.2.3 By Application – Global Clinical Whole Exome Sequencing (WES) Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Clinical Whole Exome Sequencing (WES) Market Size, 2022 & 2029
6.2 By Region – Global Clinical Whole Exome Sequencing (WES) Revenue & Forecasts
6.2.1 By Region – Global Clinical Whole Exome Sequencing (WES) Revenue, 2018-2023
6.2.2 By Region – Global Clinical Whole Exome Sequencing (WES) Revenue, 2024-2029
6.2.3 By Region – Global Clinical Whole Exome Sequencing (WES) Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Clinical Whole Exome Sequencing (WES) Revenue, 2018-2029
6.3.2 US Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.3.3 Canada Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.3.4 Mexico Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Clinical Whole Exome Sequencing (WES) Revenue, 2018-2029
6.4.2 Germany Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.4.3 France Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.4.4 U.K. Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.4.5 Italy Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.4.6 Russia Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.4.7 Nordic Countries Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.4.8 Benelux Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Clinical Whole Exome Sequencing (WES) Revenue, 2018-2029
6.5.2 China Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.5.3 Japan Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.5.4 South Korea Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.5.5 Southeast Asia Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.5.6 India Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Clinical Whole Exome Sequencing (WES) Revenue, 2018-2029
6.6.2 Brazil Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.6.3 Argentina Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Clinical Whole Exome Sequencing (WES) Revenue, 2018-2029
6.7.2 Turkey Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.7.3 Israel Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.7.4 Saudi Arabia Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
6.7.5 UAE Clinical Whole Exome Sequencing (WES) Market Size, 2018-2029
7 Clinical Whole Exome Sequencing (WES) Companies Profiles
7.1 CentoXome
7.1.1 CentoXome Company Summary
7.1.2 CentoXome Business Overview
7.1.3 CentoXome Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.1.4 CentoXome Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.1.5 CentoXome Key News & Latest Developments
7.2 Mayo Clinic Laboratories
7.2.1 Mayo Clinic Laboratories Company Summary
7.2.2 Mayo Clinic Laboratories Business Overview
7.2.3 Mayo Clinic Laboratories Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.2.4 Mayo Clinic Laboratories Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.2.5 Mayo Clinic Laboratories Key News & Latest Developments
7.3 Baylor Genetics
7.3.1 Baylor Genetics Company Summary
7.3.2 Baylor Genetics Business Overview
7.3.3 Baylor Genetics Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.3.4 Baylor Genetics Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.3.5 Baylor Genetics Key News & Latest Developments
7.4 Blueprint Genetics
7.4.1 Blueprint Genetics Company Summary
7.4.2 Blueprint Genetics Business Overview
7.4.3 Blueprint Genetics Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.4.4 Blueprint Genetics Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.4.5 Blueprint Genetics Key News & Latest Developments
7.5 GeneDx
7.5.1 GeneDx Company Summary
7.5.2 GeneDx Business Overview
7.5.3 GeneDx Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.5.4 GeneDx Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.5.5 GeneDx Key News & Latest Developments
7.6 CD Genomics
7.6.1 CD Genomics Company Summary
7.6.2 CD Genomics Business Overview
7.6.3 CD Genomics Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.6.4 CD Genomics Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.6.5 CD Genomics Key News & Latest Developments
7.7 Illumina
7.7.1 Illumina Company Summary
7.7.2 Illumina Business Overview
7.7.3 Illumina Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.7.4 Illumina Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.7.5 Illumina Key News & Latest Developments
7.8 Thermo Fisher
7.8.1 Thermo Fisher Company Summary
7.8.2 Thermo Fisher Business Overview
7.8.3 Thermo Fisher Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.8.4 Thermo Fisher Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.8.5 Thermo Fisher Key News & Latest Developments
7.9 Labassure
7.9.1 Labassure Company Summary
7.9.2 Labassure Business Overview
7.9.3 Labassure Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.9.4 Labassure Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.9.5 Labassure Key News & Latest Developments
7.10 Yale Medicine
7.10.1 Yale Medicine Company Summary
7.10.2 Yale Medicine Business Overview
7.10.3 Yale Medicine Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.10.4 Yale Medicine Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.10.5 Yale Medicine Key News & Latest Developments
7.11 Genosalut
7.11.1 Genosalut Company Summary
7.11.2 Genosalut Business Overview
7.11.3 Genosalut Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.11.4 Genosalut Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.11.5 Genosalut Key News & Latest Developments
7.12 Caris Life Sciences
7.12.1 Caris Life Sciences Company Summary
7.12.2 Caris Life Sciences Business Overview
7.12.3 Caris Life Sciences Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.12.4 Caris Life Sciences Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.12.5 Caris Life Sciences Key News & Latest Developments
7.13 InterGenetics
7.13.1 InterGenetics Company Summary
7.13.2 InterGenetics Business Overview
7.13.3 InterGenetics Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.13.4 InterGenetics Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.13.5 InterGenetics Key News & Latest Developments
7.14 Genomics and Pathology Services (GPS)
7.14.1 Genomics and Pathology Services (GPS) Company Summary
7.14.2 Genomics and Pathology Services (GPS) Business Overview
7.14.3 Genomics and Pathology Services (GPS) Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.14.4 Genomics and Pathology Services (GPS) Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.14.5 Genomics and Pathology Services (GPS) Key News & Latest Developments
7.15 3billion
7.15.1 3billion Company Summary
7.15.2 3billion Business Overview
7.15.3 3billion Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.15.4 3billion Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.15.5 3billion Key News & Latest Developments
7.16 Broad Genomic
7.16.1 Broad Genomic Company Summary
7.16.2 Broad Genomic Business Overview
7.16.3 Broad Genomic Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.16.4 Broad Genomic Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.16.5 Broad Genomic Key News & Latest Developments
7.17 Roche
7.17.1 Roche Company Summary
7.17.2 Roche Business Overview
7.17.3 Roche Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.17.4 Roche Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.17.5 Roche Key News & Latest Developments
7.18 Novogene
7.18.1 Novogene Company Summary
7.18.2 Novogene Business Overview
7.18.3 Novogene Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.18.4 Novogene Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.18.5 Novogene Key News & Latest Developments
7.19 BGI Genomics
7.19.1 BGI Genomics Company Summary
7.19.2 BGI Genomics Business Overview
7.19.3 BGI Genomics Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.19.4 BGI Genomics Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.19.5 BGI Genomics Key News & Latest Developments
7.20 Shanghai Jingzhou Genomics
7.20.1 Shanghai Jingzhou Genomics Company Summary
7.20.2 Shanghai Jingzhou Genomics Business Overview
7.20.3 Shanghai Jingzhou Genomics Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.20.4 Shanghai Jingzhou Genomics Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.20.5 Shanghai Jingzhou Genomics Key News & Latest Developments
7.21 Shihe Gene Biotechnology
7.21.1 Shihe Gene Biotechnology Company Summary
7.21.2 Shihe Gene Biotechnology Business Overview
7.21.3 Shihe Gene Biotechnology Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.21.4 Shihe Gene Biotechnology Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.21.5 Shihe Gene Biotechnology Key News & Latest Developments
7.22 JUNO Genomics
7.22.1 JUNO Genomics Company Summary
7.22.2 JUNO Genomics Business Overview
7.22.3 JUNO Genomics Clinical Whole Exome Sequencing (WES) Major Product Offerings
7.22.4 JUNO Genomics Clinical Whole Exome Sequencing (WES) Revenue in Global Market (2018-2023)
7.22.5 JUNO Genomics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer